StreetInsider.com News Articles

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results

Fri, 24 Jul 2026 03:20:00 -0400

Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China

INCHEON, Korea--(BUSINESS WIRE)-- Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

INCHEON, Korea--(BUSINESS WIRE)-- Third paragraph, second sentence of release should read: Revenue and operating profit in the first quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively. (instead of Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.).

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Thu, 23 Apr 2026 23:59:00 -0400

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

INCHEON, Korea--(BUSINESS WIRE)-- Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1.

The updated release reads:

SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first